PTH assays in dialysis patients: Practical considerations.

Area of Science:

• Endocrinology
• Nephrology
• Clinical Chemistry

Background:

• Parathyroid hormone (PTH) 1-84 is the primary active hormone, but circulating fragments complicate measurements.
• PTH is a key biomarker for bone turnover in dialysis patients, yet fragment roles are unclear.

Discussion:

• PTH assays exhibit significant variability in detecting different PTH forms (e.g., PTH 1-84, N-terminal, C-terminal fragments).
• Assay evolution from first to third generation aimed to improve specificity, but substantial inter-assay differences persist.
• Reduced kidney function alters the PTH 1-84/non-PTH 1-84 ratio, impacting interpretation.

Key Insights:

• Current PTH assays lack uniform specificity for circulating PTH forms.
• Substantial inter-assay variations necessitate caution when interpreting absolute PTH values.
• Targets based on multiples of the upper limit of normal (ULN) are preferred over absolute intact PTH (iPTH) values.

Outlook:

• Future assays need improved specificity for biologically active PTH 1-84.
• Standardization of PTH measurement methods is essential for reliable clinical decision-making.
• Further research into the biological roles of PTH fragments is warranted.